Stockscreener 앱 받기
7.75
2.02%
-0.16
시간 외 거래:
7.54
-0.21
-2.71%
전일 마감가:
$7.91
열려 있는:
$7.9
하루 거래량:
129.29K
Relative Volume:
0.33
시가총액:
$75.35M
수익:
$21.73M
순이익/손실:
$-91.17M
주가수익비율:
-10.47
EPS:
-0.74
순현금흐름:
$-286.43M
1주 성능:
-0.64%
1개월 성능:
-7.07%
6개월 성능:
-66.59%
1년 성능:
-62.01%
1일 변동 폭
$7.70
$8.2196
1주일 범위
$7.25
$8.24
52주 변동 폭
$5.80
$38.40
Bluebird Bio Inc Stock (BLUE) Company Profile
명칭
Bluebird Bio Inc
전화
339-499-9300
주소
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
BLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
7.75 | 75.35M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-11-15 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-08-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-12-11 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2023-12-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-19 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-28 | 개시 | JP Morgan | Overweight |
| 2023-03-07 | 개시 | Robert W. Baird | Outperform |
| 2022-08-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-07 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-11-08 | 재확인 | Barclays | Equal Weight |
| 2021-11-08 | 재확인 | Canaccord Genuity | Hold |
| 2021-11-08 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-11-08 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | 재확인 | Wedbush | Neutral |
| 2021-11-08 | 재확인 | Wells Fargo | Equal Weight |
| 2021-08-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-08-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | 재개 | William Blair | Mkt Perform |
| 2021-08-09 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-03-10 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-02-17 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-02-16 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-11-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-11-02 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | 개시 | Mizuho | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-27 | 업그레이드 | Stifel | Hold → Buy |
| 2020-02-19 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | 재개 | BofA/Merrill | Buy |
| 2020-02-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-10-01 | 개시 | Stifel | Hold |
| 2019-08-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | 업그레이드 | Maxim Group | Hold → Buy |
모두보기
Bluebird Bio Inc 주식(BLUE)의 최신 뉴스
bluebird bio (NASDAQ:BLUE) Share Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Sickle Cell Treatment Market Focusing on Trends and Innovations - openPR
bluebird bio Q4 EPS Estimate Increased by Leerink Partnrs - MarketBeat
Cantor Fitzgerald Predicts bluebird bio FY2025 Earnings - MarketBeat
Sickle Cell Disease Pipeline 2024: Comprehensive Clinical - openPR
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD - MSN
Cantor Fitzgerald Estimates bluebird bio FY2025 Earnings - MarketBeat
Long-Term Investors in bluebird bio Inc (NASDAQ: BLUE) should - openPR
bluebird bio, Inc. (NASDAQ:BLUE) Short Interest Update - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Adrenoleukodystrophy Drugs Market Is Booming Worldwide - openPR
Brokerages Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $49.14 - Defense World
FDA investigating safety risks of bluebird's Skysona - MSN
bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World
National Resilience to lay off 120 in North Carolina - Manufacturing Dive
Bluebird bio CEO Andrew Obenshain sells $1,293 in stock By Investing.com - Investing.com Nigeria
Bluebird bio chief medical officer sells $175 in stock By Investing.com - Investing.com Australia
Bluebird bio CEO Andrew Obenshain sells $1,293 in stock - Investing.com
Bluebird bio chief medical officer sells $175 in stock - Investing.com
bluebird bio (NASDAQ:BLUE) Stock Price Passes Below 200-Day Moving AverageHere's Why - MarketBeat
Gene Therapy Market Generated Opportunities, Future Scope by 2031 | GlaxoSmithKline plc, Bluebird Bio, Inc. - openPR
Biotech manufacturer plans to cut 120 jobs in Durham - WRAL News
Hemoglobinopathies Market Projected to Show Strong Growth| - openPR
Gene Therapy Market Generated Opportunities, Future Scope - openPR
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38% - Simply Wall St
Barclays Issues Positive Forecast for bluebird bio (NASDAQ:BLUE) Stock Price - Defense World
bluebird bio's SWOT analysis: gene therapy stock faces cash crunch amid launch - Investing.com
Barclays Forecasts Strong Price Appreciation for bluebird bio (NASDAQ:BLUE) Stock - MarketBeat
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
bluebird bio, Inc. (NASDAQ:BLUE) Sees Significant Decrease in Short Interest - MarketBeat
Once high-flying, bluebird bio now faces an uncertain future - The Business Journals
Gene Therapy Market Analysis,Growth, Insights and Future Outlook | Exactitude Consultancy - GlobeNewswire Inc.
Five things you need to know, and baby mind control - The Business Journals
Bluebird Bio (BLUE) Shares Surge Amid Market Activity - GuruFocus.com
2seventy bio: All In On ABECMA Multiple Myeloma Treatment - Seeking Alpha
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Gene Therapy For Rare Disease Market Overall Study Report - openPR
bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gene Therapy Market Huge Growth in Future Scope 2024-2031 | - openPR
Baird cuts bluebird bio price target on near-term dilution By Investing.com - Investing.com Canada
bluebird bio (NASDAQ:BLUE) Shares Up 15.3%Time to Buy? - MarketBeat
Baird cuts bluebird bio price target on near-term dilution - Investing.com
Cell and Gene Therapy Drug Delivery Devices Market to Witness - openPR
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch By Investing.com - Investing.com South Africa
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch - Investing.com
Bluebird Bio Inc (BLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):